<DOC>
	<DOCNO>NCT00434629</DOCNO>
	<brief_summary>Patients B-cell lymphoma relapse autologous transplant tend poor prognosis . Currently , standard treatment patient . Bexxar radioactive antibody therapy show 60-80 % response rate non-transplanted patient relapse B-cell lymphoma . This study test safety efficacy Bexxar treatment patient whose B-cell lymphoma relapse autologous transplant .</brief_summary>
	<brief_title>Safety Efficacy Bexxar Therapy Treatment Relapsed/Residual B-Cell Lymphoma After Autologous Transplant</brief_title>
	<detailed_description>High-dose chemotherapy follow autologous stem cell transplantation ( ASCT ) become standard care relapsed/refractory chemotherapy-sensitive non-Hodgkin 's lymphoma ( NHL ) . However , one-half two-thirds patient relapse ASCT , subsequent poor prognosis , new therapy urgently need patient population . Radioimmunotherapy ( RIT ) single agent therapy patient CD20 antigen-expressing relapse refractory low-grade , follicular , transform NHL demonstrate overall response rate 60-80 % approve FDA use set . While RIT currently investigation component conditioning regimens ASCT , safety efficacy RIT ASCT yet well describe . We conduct single-center Phase I dose-escalation trial Bexxar ( Tositumomab 131I Tositumomab ) treatment relapse residual CD20 antigen-expressing B-cell lymphoma follow ASCT . Our primary aim determine safety , dose-limiting toxicity , maximum tolerate dose Bexxar post-ASCT patient population . Our secondary aim describe overall response rate , progression-free survival , time treatment failure , overall survival . Should Bexxar prove safe population , subsequent trial design investigate efficacy RIT post-transplant setting .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Iodine-131 anti-B1 antibody</mesh_term>
	<criteria>CD20 positive Bcell lymphoma Confirmed relapsed/refractory disease follow autologous transplant Age ≤ 75 year Performance status 0 1 Creatinine ≤ 1.5 calculate creatinine clearance ≥ 60 ml/min Total bilirubin , AST , ALT ≤ 1.5 x upper limit normal ( unless bilirubin due Gilbert 's ) No active CNS disease No detectable bone marrow involvement lymphoma histopathologic bone marrow examination Bone marrow cellularity ≥ 15 % histopathologic bone marrow examination Availability adequate store autologous stem cell product ( ≥ 2 x 106 CD34+ cells/kg ) Active infection Pregnant woman exclude study Subjects use contraceptive exclude study ANC ≤ 1,500/μL and/or platelet count ≤ 100,000/μL Life expectancy ≤ 2 month Prior antiBcell radioimmunotherapy ( e.g. , Zevalin Bexxar ) [ Patients receive prior antiBcell monoclonal antibody therapy ( e.g. , rituximab epratuzumab ) NOT exclude . ] Prior total body radiation therapy Positive human antimouse antibody ( HAMA ) test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>lymphoma</keyword>
	<keyword>Non-Hodgkin 's lymphoma</keyword>
	<keyword>B-cell lymphoma</keyword>
	<keyword>Radioimmunotherapy</keyword>
	<keyword>Bexxar</keyword>
	<keyword>tositumomab</keyword>
	<keyword>autologous hematopoietic stem cell transplantation</keyword>
</DOC>